-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonmya in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonmya in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonmya in Alzheimer's Disease Drug Details: TNX-102 SL (cyclobenzaprine hydrochloride, Tonmya) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INBRX-106 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INBRX-106 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INBRX-106 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
Post-Traumatic Stress Disorder (PTSD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Post-Traumatic Stress Disorder (PTSD) Clinical Trial Report Overview A total of 704 post-traumatic stress disorder (PTSD) clinical trials were conducted as of January 2024. The PTSD clinical trial report provides a comprehensive understanding of the PTSD clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       North...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNX-102 in Fibromyalgia (Fibromyalgia Syndrome)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TNX-102 in Fibromyalgia (Fibromyalgia Syndrome) Drug Details: TNX-102 SL (cyclobenzaprine hydrochloride, Tonmya) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNX-102 in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TNX-102 in Alzheimer's Disease Drug Details: TNX-102 SL (cyclobenzaprine hydrochloride, Tonmya) is under development for...
-
Product Insights
Smallpox – Drugs In Development, 2023
Global Markets Direct’s, ‘Smallpox - Drugs In Development, 2023’, provides an overview of the Smallpox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Monkeypox – Drugs In Development, 2023
Global Markets Direct’s, ‘Monkeypox - Drugs In Development, 2023’, provides an overview of the Monkeypox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Monkeypox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Radiation Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Radiation Injury - Drugs In Development, 2023’, provides an overview of the Radiation Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Heart Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Heart Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Heart Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Heart Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Fibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Fibromyalgia (Fibromyalgia Syndrome) - Drugs In Development, 2023’, provides an overview of the Fibromyalgia (Fibromyalgia Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibromyalgia (Fibromyalgia Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...